You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds

    SBC: FirstString Research, Inc            Topic: NIDDK

    Project Summary/Abstract According to the ADA, 25.8 million children and adults have diabetes. Diabetics have an increased risk of complications such as heart disease and are prone to impaired wound healing. A major cause of morbidity and hospitalizationis diabetic foot ulceration (DFUs) that may result in infection, gangrene, amputations requiring prolonged hospitalization, costly treatments, an ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds

    SBC: FirstString Research, Inc            Topic: 200

    DESCRIPTION provided by applicant According to the ADA million children and adults have diabetes Diabetics have an increased risk of complications such as heart disease and are prone to impaired wound healing A major cause of morbidity and hospitalization is diabetic foot ulceration DFUs that may result in infection gangrene amputations requiring prolonged hospitalization costly tr ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Synthetic microparticle malaria vaccine

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION provided by applicant This Phase II project will develop a novel synthetic microparticle vaccine for malaria using the T BT epitopes of the circumsporozoite CS protein of Plasmodium falciparum the causative agent of human malaria There is no approved vaccine for malaria a disease that causes up to million new infections and million deaths each year in the developing wor ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A serologic assay to measure successful Lyme borreliosis antibiotic therapy

    SBC: L2 DIAGNOSTICS LLC            Topic: R

    DESCRIPTION provided by applicant Lyme disease LD caused by the Ixodes tick borne spirochete Borrelia burgdorferi Bb is the most common vector borne disease in the United States Despite public health preventive measures the annual confirmed case incidence has risen to over the vast majority of which occur in the Northeast Disseminated infection causes disease in the skin heart ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Gene Based Therapy for Congestive Heart Failure P2 SBIR

    SBC: Nanocor Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Congestive heart failure is a major cause of morbidity and mortality in the United States. While progress in conventional treatments is making steady and incremental gains to reduce heart failure mortality, there is a critical need to explore new therapeutic approaches. It is now apparent that gene therapy has broader potential in diseases such as congestive he ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Peptide-coated skin substitutes for the treatment of burn injuries and wounds

    SBC: AFFINERGY, LLC            Topic: 300

    DESCRIPTION provided by applicant Burn injuries and chronic wounds present a significant burden to patients and the US healthcare system Each year in the US there are burns that require medical treatment and burn patients that require hospitalization The mortality rate associated with severe burns can be as high as with of patient deaths arising from infection In add ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. IGF::OT::IGF SBIR Topic 314 Phase II- 3D Human Tumor Co-culture System for Accurate Prediction of Clinical Efficacy.

    SBC: KIYATEC, LLC            Topic: NCI

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Novel therapeutics for fatty liver disease and type-II diabetes

    SBC: SOUTHEAST TECHINVENTURES INC            Topic: 200

    DESCRIPTION provided by applicant Western lifestyle and diet have spurred the growth of numerous obesity related disorders in the US including metabolic syndrome and type diabetes to epidemic proportions However less well known is the rising epidemic of non alcoholic fatty liver disease NAFLD NAFLD ranges from mild hepatosteatosis to severe fibrosis or cirrhosis and is initially charac ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a drug discovery platform for human islets

    SBC: Zen-Bio, Inc.            Topic: 200

    DESCRIPTION provided by applicant Diabetes and diabetes related co morbidities are at epidemic proportions and an enormous burden to our healthcare system Although there has been significant progress in defining the causative factors and molecular mechanisms involved in both type and type diabetes it remains an overwhelming challenge to identify efficacious therapeutic modalities Novel a ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant Current testing for Lyme disease is suboptimal because it requires two assay platforms including one with subjective interpretation of results and because it has lower sensitivity in the early stage of the illness Infection with Borrelia burgdorferi the causative agent of Lyme disease is transmitted by the bite of an Ixodid tick and results in uniformly lo ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government